A review of cetuximab and panitumumab resistance found that intrinsic resistance often stems from pre-existing KRAS, NRAS, and BRAF mutations, while acquired resistance develops through clonal evolution under therapeutic pressure. (Pharmaceuticals)
Review Examines Resistance Mechanisms to Anti-EGFR Therapies
The CRC Digest